Videos

A group of empowering women leaders in neurology explore the transformative impact of women neurologists on the medical workforce and the strides toward a more inclusive neurology field.

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending February 2, 2025. [WATCH TIME: 4 minutes]

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program detailed advancements and strategies in using neuromodulation for LGS, as well as the future research needed to expand these approaches. [WATCH TIME: 4 minutes]

The chief medical advisor at the Muscular Dystrophy Association shared key highlights of what attendees can expect at the 2025 MDA Clinical and Scientific Conference. [WATCH TIME: 4 minutes]

The chief of neuroinfectious diseases and global neurology at Northwestern Medicine talked about a relatively new autoimmune condition, marked by mitochondrial dysfunction. [WATCH TIME: 2 minutes]

The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about refining multiple sclerosis in line with the updated diagnostic criteria. [WATCH TIME: 5 minutes]

Givinostat emerges as a promising oral treatment for muscle disorders, showing improved patient outcomes and broad applicability despite some side effects.

Explore the unique benefits and challenges of Vamorolone, a new steroid for Duchenne muscular dystrophy, compared to traditional treatments.

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program discussed the complications associated with neurostimulation in patients with LGS and strategies to mitigate these issues. [WATCH TIME: 2 minutes]

Neurology News Network. for the week ending January 25, 2025. [WATCH TIME: 4 minutes]

The chief executive officer and cofounder of Amprion discussed the integration process of a novel a-synuclein seed amplification assay used to distinguish seeds from Lewy bodies and glilal cytoplasmic inclusions. [WATCH TIME: 2 minutes]

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program provided commentary on patient selection and personalized treatment approaches when using neuromodulation devices for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

The neurointensivist and assistant professor of neurology at Boston Medical Center provided insight on a 2024 paper that defined consensus entrustable professional activities for neurocritical care advanced practice providers. [WATCH TIME: 5 minutes]

The professor of neurology at University of Florence talked about how early intervention, broader assessment tools, and personalized approaches are essential for effectively managing multiple sclerosis. [WATCH TIME: 4 minutes]

The assistant professor at The Hebrew University of Jerusalem School of Pharmacy discussed how the brain microbiome may contribute to Alzheimer through interactions with immune responses and proteins. [WATCH TIME: 5 minutes]

Experts discuss valuable endpoints in Duchenne clinical trials, emphasizing survival, respiratory health, and the importance of non-ambulatory patient measures.

Explore the evolving landscape of Duchenne muscular dystrophy treatments, including FDA-approved therapies and innovative alternatives for better patient care.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed how a recently published preclinical study adds to the understanding of neuropilin-1 in chronic pain. [WATCH TIME: 3 minutes]

At ECTRIMS 2024, the assistant professor at the University of Naples the latest multiple sclerosis diagnostic criteria, which emphasized a shift toward biologically based diagnoses. [WATCH TIME: 4 minutes]

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]

At ECTRIMS 2024, the consultant neurologist at Queen's Square MS Center in London talked about the evolving McDonald criteria to define multiple sclerosis biologically. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending January 18, 2025. [WATCH TIME: 4 minutes]

At ECTRIMS 2024, the postdoctoral researcher at Amsterdam University Medical Center talked about an evolving tool developed to predict disease progression in multiple sclerosis. [WATCH TIME: 7 minutes]

The neurologist and sleep disorder specialist at Allegheny Health Network discussed the challenges with preventing narcolepsy and the strategies patients can take to improve their overall prognosis. [WATCH TIME: 4 minutes]

The neurology resident at the University Hospital Frankfurt in Germany talked about the importance of initiating treatment early for patients with multiple sclerosis to improve long-term outcomes. [WATCH TIME: 6 minutes]

The associate professor of neurology at Harvard Medical School talked about reconsidering therapy switches for NMOSD, incorporating safety failures like recurrent infections, and prioritizing real-world studies to validate findings. [WATCH TIME: 5 minutes]